Published Date: 02 Mar 2023
Many doctors have accused hospitals and large hospitals of opposing quality care and promoting violence. Others disagree.
Read Full NewsCuda discussed the potential of the NIH toolbox to easily assess cognitive effects in clinical trials.
Friedberg discusses the inconsistent clinical pathways from disease progression to intervention in patients with a pair of highly deadly lung diseases.
New findings from the LUMINA trial reveal AMX0114's safety in ALS patients, paving the way for further research and potential treatment advancements.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on neuromodulation for Parkinson disease!
Asthma Biologic Adherence Shaped by Psychological, Clinical, Systemic Factors
Post-NICU PM2.5 Exposure Raises Asthma Risk in Children With Bronchopulmonary Dysplasia
Teva Pharmaceuticals Submits NDA on TEV-‘749 for Schizophrenia to the FDA
1.
New CAR T-Cell Therapy Approved for Leukemia
2.
Cancer Diagnoses Slow to Recover From Effects of COVID Pandemic
3.
Researchers publish action plan to address appendiceal cancer enigmas
4.
In patients with advanced lung cancer, cemiplimab combined with chemotherapy extends life and enhances quality of life.
5.
Words matter to people living with cancer. Here's how verbal microaggressions affect their mental state
1.
All About Ferric Gluconate – The Best Source Of Iron For Anemia
2.
Landmark Medical Oncology Trials Redefining Early Breast Cancer Management
3.
The Essential Roadmap for Nutritional Excellence in Head and Neck Cancer Care
4.
Beyond the Biopsy: Decoding Tumor Biology Through the Lens of Radiogenomics
5.
Deciphering FFR: A Comprehensive Guide to Understanding Its Meaning
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II
2.
Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC
3.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part II
4.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
5.
Should We Use DARA Up Front As First-Line Therapy in MM? - Part II
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation